 |
4 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- || epetraborole (AN3365) / AN2 Therap, FP-1039 / Amgen
Clinical, P1 data, Journal, Combination therapy: A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. (Pubmed Central) - Mar 4, 2021
Conclusion At 15 mg/kg weekly, GSK3052230 was well tolerated in combination with pemetrexed/cisplatin and durable responses were observed. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.
- || Clinical, P1 data, Journal, Combination therapy: An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. (Pubmed Central) - Jul 22, 2020
GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.
- ||| FP-1039 / Amgen
Trial completion, Enrollment change, Combination therapy: Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (clinicaltrials.gov) - Nov 14, 2017
P1, N=65, Completed, Sponsor: GlaxoSmithKline
Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug. Active, not recruiting --> Completed | N=120 --> 65
- || FP-1039 / Amgen
Trial primary completion date, Combination therapy: Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (clinicaltrials.gov) - May 1, 2017
P1, N=120, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=120 --> 65 Trial primary completion date: Apr 2017 --> Sep 2017
- || FP-1039 / Amgen
Enrollment closed, Trial primary completion date, Combination therapy: Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (clinicaltrials.gov) - Dec 16, 2016
P1, N=120, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2017 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Apr 2017
- ||| FP-1039 / Amgen
Enrollment open, Combination therapy: Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (clinicaltrials.gov) - Nov 6, 2013
P1, N=104, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Apr 2017 Not yet recruiting --> Recruiting
- ||| FP-1039 / Amgen
New P1 trial, Combination therapy: Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (clinicaltrials.gov) - Jun 2, 2013
P1, N=104, Recruiting, Sponsor: GlaxoSmithKline
- | FP-1039 / Amgen
Trial suspension, Combination therapy, Metastases: A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - Oct 10, 2012
P1b, N=54, Suspended, Sponsor: Human Genome Sciences Inc., a GSK Company
Not yet recruiting --> Recruiting Not yet recruiting --> Suspended
- FP-1039 / Amgen
Enrollment change, Combination therapy, Metastases: A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies (clinicaltrials.gov) - Jun 13, 2012
P1b, N=54, Suspended, Sponsor: Human Genome Sciences Inc., a GSK Company
Not yet recruiting --> Suspended N=72 --> 54
- FP-1039 / Amgen
Trial withdrawal, Metastases: Study of FP-1039 in Subjects With Endometrial Cancers (clinicaltrials.gov) - Mar 7, 2012
P2, N=0, Withdrawn, Sponsor: Five Prime Therapeutics, Inc.
N=72 --> 54 Recruiting --> Withdrawn
- FP-1039 / Amgen
Enrollment change, Metastases: Study of FP-1039 in Subjects With Endometrial Cancers (clinicaltrials.gov) - Mar 7, 2012
P2, N=0, Withdrawn, Sponsor: Five Prime Therapeutics, Inc.
Recruiting --> Withdrawn N=10 --> 0